{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.2203","value":"-0.014"},{"groupId":"OG001","spread":"0.2674","value":"-0.029"}]}],"title":"Week 6, n=253, 125"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.2148","value":"-0.040"},{"groupId":"OG001","spread":"0.1969","value":"0.007"}]}],"title":"Week 12, n=219, 86"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.2305","value":"-0.023"},{"groupId":"OG001","spread":"0.1466","value":"-0.006"}]}],"title":"Week 18, n=196, 62"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.2420","value":"-0.025"},{"groupId":"OG001","spread":"0.2411","value":"-0.001"}]}],"title":"Week 24, n=166, 51"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.1961","value":"0.030"},{"groupId":"OG001","spread":"0.2015","value":"-0.005"}]}],"title":"Week 36, n=98, 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"description":"The EQ-5D is comprised of a 5-item health status measure and a visual analogue rating scale, and measures mobility, self-care, usual activities, pain, discomfort, and anxiety/depression. Responses to each of the 5 health states are measured on a 3-point scale (no, moderate, and extreme problems). Scoring of the EQ-5D yields an index-based summary score (Index), through application of societal weights, and a VAS score (VAS). Index is interpreted on a continuum from 1.0 (best possible health) to 0 (represents dead), to some health sates being worse than dead (\\<0).","dispersionType":"Standard Deviation","groups":[{"description":"Pazopanib 800 mg (tablets) administered orally once a day","id":"OG000","title":"Pazopanib 800 mg"},{"description":"Matching placebo administered orally once a day","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"Participants in the ITT Population who completed HRQOL assessments at Baseline and had at least one post-baseline assessment are included. Only participants who were on treatment at the given time point were asked to complete the questionnaire, and only those who completed the questionnaire could be analyzed for each individual time point.","reportingStatus":"POSTED","timeFrame":"Baseline and Weeks 6, 12, 18, 24, and 48","title":"Adjusted Mean Change From Baseline in the Index Score of the EQ-5D (EuroQoL [Quality of Life]-5D) Questionnaire at Weeks 6, 12, 18, 24, and 48","type":"SECONDARY","unitOfMeasure":"points on a scale"}